Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals (EGRX) is a fully integrated specialty pharmaceutical company advancing therapies in oncology, central nervous system disorders, and pediatric critical care. This page serves as the definitive source for official company announcements, clinical trial updates, and regulatory developments.
Investors and healthcare professionals will find curated press releases detailing FDA submissions, partnership agreements, and research breakthroughs. Our repository includes updates on product approvals, manufacturing advancements, and strategic initiatives across EGRX's therapeutic portfolio.
Key content categories include quarterly financial results, clinical study outcomes, intellectual property milestones, and market expansion efforts. All materials are sourced directly from company filings and verified announcements to ensure reliability.
Bookmark this page for streamlined access to EGRX's latest developments. For comprehensive tracking of the company's progress in addressing complex medical needs through innovative pharmaceuticals, we recommend checking back regularly.
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced that its Board amended and extended the company’s limited duration stockholder rights plan by one year to October 30, 2026, effective immediately.
The amendment was made in response to ongoing significant trading-price dislocation and increases the potential dilution an acquirer would face if the plan is triggered. Rights become exercisable if a person or group acquires ≥10% beneficial ownership (or ≥15% for passive institutional investors). Grandfathered holders above the thresholds remain at current levels but may not increase ownership without triggering the plan.
Each exercisable Right permits purchase for $20.00 of shares with a market value equal to twice that price; the Rights Plan will expire automatically on October 30, 2026 unless redeemed or exchanged earlier.
Eagle Pharmaceuticals (OTCMKTS: EGRX) reported results from its 2025 annual meeting held virtually on October 17, 2025. Of 13,157,754 shares outstanding, 10,769,820 shares (≈82%) were present or represented by proxy.
All four director nominees were elected: Class I nominees Michael Graves and Richard Edlin (terms to 2027), and Class II nominees Jennifer Simpson and Luciana Borio (terms to 2028). Broker non-votes totaled 1,064,408. The stockholder vote also ratified BDO USA, P.C. as auditor for fiscal 2025 (FOR 9,011,921; AGAINST 1,700,348; ABSTAIN 57,551).
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced on Oct 15, 2025 that its unaudited financial statements for the three and six months ended June 30, 2025 are available for investors.
The statements can be accessed via the company’s investor relations page at https://investor.eagleus.com/events-presentations.
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced that its unaudited financial statements for the three months ended March 31, 2025 are available online. The documents can be accessed at the company's investor events and presentations page for review by shareholders and analysts.
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced the availability of proxy materials for its upcoming 2025 Annual Meeting of Stockholders, scheduled for October 17, 2025 at 10:00 a.m. Eastern Time. The meeting will be held virtually.
Stockholders of record as of August 18, 2025 will receive a Notice of Internet Availability of Proxy Materials. All proxy materials, including the notice, proxy information statement, and proxy card, along with the company's audited financial statements for 2023 and 2024, can be accessed through www.proxyvote.com and the company's investor relations website.
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced the appointment of Abhinav "Abi" Jain as an independent member of its Board of Directors. Jain, an Analyst at Nantahala Capital Management which holds approximately 38% of Eagle's shares, will serve as a Class III director until the 2026 Annual Meeting and join the Compensation and Nominating committees.
As part of a cooperation agreement with Nantahala, Eagle has committed to appointing a second independent director by May 15, 2026. Jain brings experience from his roles at Nantahala and Angelo, Gordon & Co., with expertise in specialty and generic pharmaceuticals investments.
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced its 2025 Annual Meeting of Stockholders will be held on October 17, 2025. The company has set August 18, 2025 at 5 p.m. Eastern Time as the record date for stockholder participation. Specific details regarding the meeting time and location will be communicated directly to eligible stockholders through official meeting materials.
Eagle Pharmaceuticals (EGRX) has entered into a $69 million royalty purchase agreement with Blue Owl Capital to sell its royalty interest in BENDEKA® (bendamustine hydrochloride injection) U.S. sales. The transaction provides immediate, non-dilutive capital to Eagle.
Under the agreement, Eagle will receive the upfront payment in exchange for a prespecified royalty interest for Q4 2024 and 100% thereafter, up to 1.3x the purchase price. After reaching this cap, future royalty payments will revert to Eagle.
The company plans to use the proceeds to fully repay its Credit Agreement, including $27.5 million in term loan and $25 million in revolving credit facility. Remaining funds will support general corporate purposes, including ongoing R&D programs like CAL02 for severe community-acquired bacterial pneumonia and EA 114 for hormone-receptor-positive metastatic breast cancer.
Eagle Pharmaceuticals (EGRX) has announced an amendment to its duration stockholder rights plan, doubling the initial purchase price of preferred share purchase rights from $10.00 to $20.00. The Rights Plan targets any person or group that acquires 10% ownership (15% for passive institutional investors) of company stock without Board approval.
The amendment responds to significant stock price dislocation and aims to increase potential dilution for unauthorized acquirers. The plan's primary objectives are to protect long-term stockholder value and prevent control acquisition through open market accumulation without fair compensation. The Rights Plan will automatically expire on October 30, 2025, unless rights are redeemed or exchanged earlier.
Eagle Pharmaceuticals (EGRX) has announced its intention to file Form 25 with the SEC to complete its delisting from the Nasdaq Global Market. The company's common stock was suspended from Nasdaq trading on October 3, 2024, due to non-compliance with listing requirements, and has been trading on the OTC Expert Market since October 4, 2024. The Form 25 filing, expected on or after November 25, 2024, will finalize the delisting process and deregister the stock under Section 12(b) of the Securities Exchange Act, reducing SEC reporting obligations.
FAQ
What is the current stock price of Eagle Pharmaceut (EGRX)?
What is the market cap of Eagle Pharmaceut (EGRX)?
